http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5910428-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc2a22a9271507062ad7e07974d3c58 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-72 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 |
| filingDate | 1994-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3ec8e2196ab7ca04141bffc08f121f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dcd33daa026997f80862c33a6620014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f4f319923e11f90a62890763970b074 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_def5713d867029bda32bdf31535cb75e |
| publicationDate | 1999-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5910428-A |
| titleOfInvention | Brain-derived membrane-associated CRF binding proteins |
| abstract | PCT No. PCT/US94/12672 Sec. 371 Date Jul. 2, 1996 Sec. 102(e) Date Jul. 2, 1996 PCT Filed Nov. 7, 1994 PCT Pub. No. WO95/13372 PCT Pub. Date May 18, 1995Isolated, substantially pure mammalian brain-derived membrane-associated CRF-binding proteins and biologically active fragments thereof are provided as well as isolated and purified DNA fragments which encode the CRF binding proteins or biologically active fragments thereof or homologs of other mammalian species. By administering an amount of such CRF binding protein or a fragment thereof effective to modulate receptor activation, it is possible to modulate the action of CRF upon (a) the brain and nervous system, (b) the pituitary particularly for production of ACTH, beta endorphin and cortisol, (c) sites of inflammation, (d) the placenta, (e) the adrenal glands, (f) the gonads or (g) the gastrointestinal tract. Administration of an N-terminal fragment of the protein increases the binding site density for CRF and thus modulates its biological effect in vivo. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019382462-A1 |
| priorityDate | 1993-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 585.